Next Article in Journal
Determining Thermal Conductivity of Small Molecule Amorphous Drugs with Modulated Differential Scanning Calorimetry and Vacuum Molding Sample Preparation
Next Article in Special Issue
Oral Treatment of Spontaneously Hypertensive Rats with Captopril-Surface Functionalized Furosemide-Loaded Multi-Wall Lipid-Core Nanocapsules
Previous Article in Journal
Topical Delivery of Niacinamide: Influence of Binary and Ternary Solvent Systems
Open AccessArticle

Niosomal Formulation of a Lipoyl-Carnosine Derivative Targeting TRPA1 Channels in Brain

Department of Chemistry “Ugo Schiff”, University of Florence, 50019 Florence, Italy
Department of Health Sciences, Clinical Pharmacology and Oncology Unit, University of Florence, 50139 Florence, Italy
Department of Biotechnologies and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy
Authors to whom correspondence should be addressed.
Pharmaceutics 2019, 11(12), 669;
Received: 15 November 2019 / Revised: 4 December 2019 / Accepted: 6 December 2019 / Published: 10 December 2019
(This article belongs to the Special Issue Nanocarriers and Nanomedicine for Drug Delivery)
The transient receptor potential akyrin type-1 (TRPA1) is a non-selective cation channel playing a pivotal role in pain sensation and neurogenic inflammation. TRPA1 channels expressed in the central nervous system (CNS) have a critical role in the modulation of cortical spreading depression (CSD), which is a key pathophysiological basis of migraine pain. ADM_09 is a recently developed lipoic acid-based TRPA1 antagonist that is able to revert oxaliplatin-induced neuropathic pain and inflammatory trigeminal allodynia. In this context, aiming at developing drugs that are able to target TRPA1 channels in the CNS and promote an antioxidant effect, permeability across the blood–brain barrier (BBB) represents a central issue. Niosomes are nanovesicles that can be functionalized with specific ligands selectively recognized by transporters expressed on the BBB. In this work, the activity of ADM_09 on neocortex cultures was studied, and an efficient formulation to cross the BBB was developed with the aim of increasing the concentration of ADM_09 into the brain and selectively delivering it to the CNS rapidly after parenteral administration. View Full-Text
Keywords: TRPA1 antagonist; cortical spreading depression; blood brain barrier; niosomes TRPA1 antagonist; cortical spreading depression; blood brain barrier; niosomes
Show Figures

Graphical abstract

MDPI and ACS Style

Maestrelli, F.; Landucci, E.; De Luca, E.; Nerli, G.; Bergonzi, M.C.; Piazzini, V.; Pellegrini-Giampietro, D.E.; Gullo, F.; Becchetti, A.; Tadini-Buoninsegni, F.; Francesconi, O.; Nativi, C. Niosomal Formulation of a Lipoyl-Carnosine Derivative Targeting TRPA1 Channels in Brain. Pharmaceutics 2019, 11, 669.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop